JewishStatusOpen the app

Jewish News 24 · Aug 19, 2026

Jewish News 24 — photo status

🧬📈 MODERNA STOCK SOARS ON CANCER VACCINE BREAKTHROUGH: Moderna shares surged more than 100% Wednesday after Moderna and Merck announced the first successful Phase 3 trial of a personalized mRNA cancer vaccine. Intismeran autogene, combined with Merck’s Keytruda, met its primary and key secondary endpoints in 1,137 patients with high-risk melanoma, significantly improving recurrence-free survival and reducing the risk of the cancer spreading to distant parts of the body. The results mark a major milestone for personalized mRNA cancer therapy, though detailed trial data have not yet been released.

🧬📈 *MODERNA STOCK SOARS ON CANCER VACCINE BREAKTHROUGH:* Moderna shares surged more than 100% Wednesday after Moderna and Merck announced the first successful Phase 3 trial of a personalized mRNA cancer vaccine. Intismeran autogene, combined with Merck’s Keytruda, met its primary and key secondary endpoints in 1,137 patients with high-risk melanoma, significantly improving recurrence-free survival and reducing the risk of the cancer spreading to distant parts of the body. The results mark a major milestone for personalized mRNA cancer therapy, though detailed trial data have not yet been released.

Watch in the app All of Jewish News 24's statuses

More from Jewish News 24